HHC
TXMD icon

Hutchin Hill Capital’s TherapeuticsMD TXMD Stock Holding History

Hutchin Hill Capital’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-222
Closed -$49K – 721
2014
Q2 		$49K Buy
+222
New +$49.4K ﹤0.01% 585

Other funds holding TXMD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hutchin Hill Capital's TXMD Position: Q3 2014 in Review

Hutchin Hill Capital sold out of TherapeuticsMD (TXMD) in Q3 2014, closing a stake of 222 shares — an estimated $49K sold.

Hutchin Hill Capital first reported a position in TXMD in Q2 2014 and held it in 1 quarter. The position peaked at $49K in Q2 2014. 82 funds tracked by Wall St. Rank hold TXMD as of Q3 2014.

  • Hutchin Hill Capital reported no remaining TherapeuticsMD position as of Q3 2014 after selling out during the quarter.
  • Hutchin Hill Capital sold 222 TherapeuticsMD shares in Q3 2014, an estimated $49K.
  • Hutchin Hill Capital first reported a position in TherapeuticsMD in Q2 2014 and held it in 1 quarter.
  • Hutchin Hill Capital's TherapeuticsMD position peaked at $49K in Q2 2014.
  • 82 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2014.

Based on Hutchin Hill Capital's 13F filing for Q3 2014, filed 14 Nov 2014.